M&A Deal Summary

Sun Pharmaceutical Industries Acquires Ocular Technologies Sarl

On October 26, 2016, Sun Pharmaceutical Industries acquired information technology company Ocular Technologies Sarl from Auven Therapeutics for 40M USD

Acquisition Highlights
  • This is Sun Pharmaceutical Industries’ 1st transaction in the Information Technology sector.
  • This is Sun Pharmaceutical Industries’ largest (disclosed) transaction.
  • This is Sun Pharmaceutical Industries’ 1st transaction in South Africa.

M&A Deal Summary
Date 2016-10-26
Target Ocular Technologies Sarl
Sector Information Technology
Buyer(s) Sun Pharmaceutical Industries
Sellers(s) Auven Therapeutics
Deal Type Add-on Acquisition
Deal Value 40M USD

Target

Ocular Technologies Sarl

Lyme Park, South Africa
Ocular Technologies Sarl is a specialist enterprise communications company and turnkey services provider. The company has made its mark at the forefront of the industry as a preferred partner for large-scale corporates, SMMEs and government affiliates alike.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Sun Pharmaceutical Industries

Cranbury, New Jersey, United States
Category Company
Founded 2004
Sector Medical Products
DESCRIPTION

Sun Pharmaceutical Industries, Inc. manufactures and distributes Medical prodicts.

DEAL STATS #
Overall 3 of 3
Sector (Information Technology) 1 of 1
Type (Add-on Acquisition) 2 of 2
Country (South Africa) 1 of 1
Year (2016) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-11-25 Chattem Chemicals

Chattanooga, Tennessee, United States

Chattem Chemicals, Inc. manufactures a variety of active pharmaceutical ingredients (APIs) and performance chemicals used in consumer and industrial markets.

Buy -

Seller(S) 1

SELLER

Auven Therapeutics

Investor

Category Private Equity Firm
Founded 2007
Size Small
Type Sector Focused
DESCRIPTION

Auven Therapeutics is a private equity firm focused on investing in life science companies. Auven looks to acquire controlling ownership in promising therapeutic products or platforms and develop programs to selling them as clinically and commercially validated products to established pharmaceutical companies. Auven Therapeutics was established in 2007 and is headquartered in St. Thomas, US Virgin Islands.

DEAL STATS #
Overall 3 of 4
Sector (Information Technology) 1 of 1
Type (Add-on Acquisition) 3 of 3
Country (South Africa) 1 of 1
Year (2016) 1 of 1
Size (of disclosed) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-08-20 Sprout Pharmaceuticals

Raleigh, North Carolina, United States

Sprout Pharmaceuticals, Inc. is a life science company focused on women's sexual health. Sprout is passionate about women's sexual health and has focused solely on the delivery of a treatment option for the unmet need of premenopausal women with acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.

Sell $1.0B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-05-11 ADC Therapeutics

Epalinges, Switzerland

ADC Therapeutics a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics was founded in 2011 and is based in Epalinges, Switzerland.

Sell -
Mergr

Product

Company

Legal